Research Overview

The work in our laboratory is focused on obtaining a detailed understanding of the mechanism by which retroviral DNA is integrated into its host cell chromatin, and discovering the epigenetic factors and processes that affect its subsequent expression. Retroviruses are of special interest, not only because they are agents of disease, including cancer, but also because they are important as vehicles for the insertion of desired genes into target cells for scientific investigation and gene therapy. We exploit a broad range of investigational methods from biochemical and biophysical analyses of protein function, to in vivo studies of viral growth and cell biology. This comprehensive approach provides unique insights, and excellent opportunities for cross-discipline training and collaboration. Our continuing overarching goals are to uncover new information of fundamental importance to both virus and cell biology, and to identify new targets for therapies to treat disease.

We have made exciting progress in our investigation of the molecular structure of retroviral integrase, the enzyme that mediates insertion of viral DNA into the DNA of its host cell. With our Fox Chase collaborator, Z. Bu, Ph.D., small angle X-ray scattering (SAXS) and molecular modeling have been used to obtain the first available information concerning the shapes and structures of integrase monomers and dimers in solution. This structure can now be used to identify points of contact between the protein subunits, as well as between the protein and its DNA substrates. Such information will not only add to our understanding of this complex reaction, but may also suggest new ways to interfere with this activity, which is critical for viral replication.

We also described a system in which we detected high-frequency epigenetic gene silencing of freshly integrated retroviral DNA. We believe that such silencing may reflect a cellular anti-viral response. We published the results from our proof-of-principle studies using silent “reporter cells” to establish the validity of this system for identification of cellular factors that govern this epigenetic silencing – a phenomenon that is important to our understanding of the antiviral response as well as, the roles of epigenetic factors in normal cell development and cancer. With the help of the Fox Chase Cancer Center Translational Facility, we have used this reporter cell population to develop a robust and sensitive siRNA-based high throughput screen to identify specific host factors that participate in the maintenance of epigenetic silencing. Our results to date provide compelling evidence for roles of specific host factors and indicate that they are involved in cooperative and reinforcing interactions that mediate epigenetic silencing. Top

Description of research projects
Selected Publications

Fox Chase Programs

Extramural Affiliations

  1. Poleshko A, Einarson MB, Adams PD, Zhang R, Skalka AM, Katz RA. Identification of a functional network of human epigenetic silencing factors. J Biol Chem. Forthcoming 2009. PubMed
  2. Merkel G, Andrake MD, Ramcharan J, Skalka AM. Oligonucleotide-based assays for integrase activity. Mechanistic and Pharmacological Analyses of HIV-1 Integration. Alan Engelman, ed. Elsevier Editorial Systems for Methods. 2009 Apr;47(4):243-8. Epub 2008 Nov 14. PubMed
  3. Katz RA, Daniel R, Skalka AM. Host factors that affect provirus stability and silencing. Chapter 9 HIV1 Integrase: Mechanisms Of Action And Inhibitor Design. Wand B, and Neamati, N, eds. John Wiley and Sons, Inc., UK. Forthcoming 2009.
  4. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. Principles of Virology, 3rd edition. Vol. II. Pathogenesis and Control of Animal Viruses, 419 pages. ASM Press, Washington DC, 2009
  5. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. Principles of Virology, 3rd edition. Vol I. Molecular Biology, 569 pages. ASM Press, Washington DC, 2009.
  6. Andrake MD, Sauter MM, Boland K, Goldstein AD, Hussein M, and Skalka AM. Nuclear import of avian sarcoma virus integrase is facilitated by host cell factors. Retrovirology. 2008 August;5:73. PubMed
  7. Poleshko A, Palagin I, Zhang R, Boimel P, Castagna C, Adams PD, Skalka AM, and Katz RA. Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response. J Virol. 2008 December;82(5):2313-23. PubMed
  8. Katz RA, Jack-Scott E, Narezkina A, Palagin I, Boimel P, Kulkosky J, Nicolas E, Greger J.G, and Skalka AM. High frequency epigenetic repression and silencing of retroviruses can be antagonized by HDAC inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanisms. J Virol. 2007 January;81(6):2592-04. PubMed
  9. Ramcharan J, Colleluori DM, Merkel G, Andrake MD, and Skalka AM. Mode of Inhibition of HIV-1 integrase by a C-terminal domain-specific monoclonal antibody. Retrovirology. 2006 June; 3:34. PubMed
  10. Ramcharan J, Skalka AM. Strategies for identification of HIV-1 integrase inhibitors. Future Virol. 2006 November;1:717-31.
  11. Ason B, Knauss DJ, Balke AM, Merkel G, Skalka AM, Reznikoff WS. Targeting Tn5 transposase identifies HIV-1 inhibitors. Antimicrob. Agents Chemother. 2005 April;49:2035-43. PubMed
  12. Daniel R, Marusich E, Argyris E, Zhao R Y, Skalka AM, and Pomerantz RJ. Caffeine inhibits HIV-1 transduction of non-dividing cells. J Virol. 2005 February;79(4):2058-65. PubMed
  13. Greger JG, Katz RA, Ishov AM, Maul G, and Skalka AM. The cellular protein Daxx interacts with Avian Sarcoma Virus integrase and viral DNA to repress viral transcription. J Virol. 2005 March;79(8):4610-4618, 2005. PubMed
  14. Katz RA, Greger JG, and Skalka AM. Effects of cell cycle status on early events in retroviral replication. J Cell Biochem. 2005 April;94:880-89.
  15. Skalka AM, and Katz RA. Retroviral DNA integration and the DNA damage response. Cell Death Diff. 2005 August;2:971-78.
  16. Daniel R, Ramcharan J, Rogakou E, Taganov KD, Greger JG, Bonner W, Nussenzweig A, Katz RA, and Skalka AM Histone H2AX is phosphorylated at sites of retroviral DNA integration, but is dispensable for post-integration repair. J Biol Chem. 2004 August;279:45810-14.PubMed
  17. Narezkina, A., Taganov, K.D., Litwin, S., Stoyanova, R., Hayashi, J., Seeger, C., Skalka, A.M. and Katz, R.A. Genome-wide analyses of avian sarcoma virus integration sites. J Virol. 2004 October;78(21):11656-63.PubMed
  18. Daniel R, Katz RA, Greger J, Taganov K, Wu X, Kappes JC, and Skalka, A.M. Evidence that stable retroviral transduction and cell survival following DNA integration depends on components of the NHEJ repair pathway. J Virol. 2004 July;78(16):8573-81.PubMed
  19. Daniel R, Myers CB, Taganov K, Greger JG, Merkel G, Weber IT, Harrison RW, and Skalka AM. Characterization of a napthalene-derivative inhibitor of retroviral integrases. AIDS Res Hum Retroviruses. 2004 March;20(2):135-44.PubMed
  20. Taganov KD, Cuesta I, Daniel R, Cirillo LA, Katz RA, Zaret KS, and Skalka AM. Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. J Virol. 2004 April;78(11):5848-55.PubMed
  21. Greger J, Katz RA, Taganov K, Rall GF, and Skalka AM. Transduction of terminally differentiated neurons by Avian Sarcoma Virus. J Virol. 2004 April;78(9):4902-06.PubMed
  22. Top
All publications